The Vanguard Group, Inc. recently announced the acquisition of new stake in Zosano Pharma Corporation (NASDAQ:ZSAN). The institutional investor has increased its shareholding in the Healthcare company by 43.14% to 1.36 million shares with purchase of 0.41 million shares. This fresh investment now brings its stake to 2.50% valued currently at $1.16 million. In addition, BlackRock Fund Advisors raised its holdings by 21772.0 to 0.38 million shares.
With over 2.62 million Zosano Pharma Corporation (ZSAN) shares trading Friday and a closing price of $0.85 on the day, the dollar volume was approximately $2.22 million. The shares have shown a negative weekly performance of -9.10% and its price on 07/24/20 lost nearly -2.87%. Currently, there are 54.36M common shares owned by the public and among those 48.66M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for ZSAN have a consensus price objective of $4.33. The analysts have set the share’s price value over the next 12 months at a high of $7.00 and a low of $2.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Zosano Pharma Corporation stock is 1.70 for the next 12 months. But an upside of 87.86% will see the stock hit the forecast high price target while mean target price for the stock is $4.00.
Insiders at the company have transacted a total of 11 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 11 of these insider trades were purchases, accounting for 937,155 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Zosano Pharma Corporation are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.75 million shares of the company’s stock, all valued at over $0.64 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.55% of the shares outstanding.
Shares of Zosano Pharma Corporation (NASDAQ: ZSAN) opened at $0.87, down -$0.01 from a prior closing price of $0.88. However, the script later closed the day at $0.85, down -2.87%. The company’s stock has a 5-day price change of -9.10% and 9.00% over the past three months. ZSAN shares are trading -44.09% year to date (YTD), with the 12-month market performance down to -69.97% lower. It has a 12-month low price of $0.41 and touched a high of $3.21 over the same period. Currently, 2.62 million shares have been traded, compared to an average intraday trading volume of 1.86 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.08%, -4.37%, and -25.26% respectively.
Institutional ownership of Zosano Pharma Corporation (NASDAQ: ZSAN) shares accounts for 22.30% of the company’s 54.36M shares outstanding. Mutual fund holders own 3.60%, while other institutional holders and individual stakeholders account for 9.24% and 11.00% respectively.
It has a market capitalization of $46.04M and a beta (3y monthly) value of 2.66. The earnings-per-share (ttm) stands at -$1.82. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.88% over the week and 6.63% over the month.
Analysts forecast that Zosano Pharma Corporation (ZSAN) will achieve an EPS of -$0.14 for the current quarter, -$0.13 for the next quarter and -$0.2 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.17 while analysts give the company a high EPS estimate of -$0.1. Comparatively, EPS for the current quarter was -$0.55 a year ago. Earnings per share for the fiscal year are expected to increase by 38.70%, and 66.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Zosano Pharma Corporation (ZSAN) as a “Strong Buy” at a consensus score of 1.70. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ZSAN, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on April 17, 2019, with the firm’s price target at $8. Piper Jaffray coverage for the Zosano Pharma Corporation (ZSAN) stock in a research note released on March 24, 2017 offered a Overweight rating with a price target of $4. Ladenburg Thalmann was of a view on August 11, 2016 that the stock is Neutral, while ROTH Capital gave the stock Buy rating on November 11, 2015, issuing a price target of $11- $7. ROTH Capital on their part issued Buy rating on September 29, 2015.